Aclaris Therapeutics leverages its KINect® platform to discover covalent kinase inhibitors and dual‑targeting bispecific antibodies that modulate key inflammatory signaling pathways. It advances oral, topical, and biologic candidates for immuno‑inflammatory conditions such as atopic dermatitis, asthma, COPD, and inflammatory bowel disease, and provides licensing and co‑development partnerships to pharmaceutical and biotechnology companies.

Biohaven Pharma is a biopharmaceutical company that discovers, develops, and commercializes novel therapies for neuroscience, immunology, and oncology. Using proprietary modular drug development platforms and strategic collaborations, it accelerates the creation of treatments for high‑unmet‑need conditions such as epilepsy, spinal muscular atrophy, and rare neurogenetic disorders.

Cerene provides an FDA‑cleared, office‑based cryotherapy system that ablates the endometrial lining to treat heavy menstrual bleeding without general anesthesia. Using a single‑use probe, the procedure delivers controlled freezing in under 10 minutes, allowing gynecologists to perform the treatment in a standard exam room with minimal downtime and pain.

Cortica provides personalized neurological therapies, including Applied Behavioral Analysis (ABA), speech, and occupational therapy, for children with autism and other developmental differences. The startup offers a coordinated, multidisciplinary approach to care, enabling measurable improvements in communication, social skills, and emotional regulation through evidence-based treatment plans.

Inspire provides an advanced, clinically proven, mask-free therapy for patients with obstructive sleep apnea who have struggled with CPAP. This solution utilizes an implantable device controlled via a remote and smartphone application to keep the airway open during sleep. The therapy offers a simplified procedure and is covered by most major commercial insurers and government health programs.

Miach Orthopaedics has developed the BEAR® Implant, a medical device that utilizes a patient's own blood to promote the healing of torn anterior cruciate ligaments (ACLs) by facilitating new tissue growth between the torn ends. This technology addresses the challenge of ACL injuries by providing a biological scaffold that is gradually replaced by the patient's healed ligament.

Nalu Medical provides a battery‑free neurostimulation system for chronic peripheral nerve pain, consisting of a subcutaneous microstimulator and a wearable therapy disc that wirelessly delivers and programs low‑amplitude electrical pulses. The modular design enables precise nerve targeting, real‑time parameter adjustment, and firmware upgrades without additional surgery, and the implant can be removed in a minor outpatient procedure.

ShiraTronics develops a neuromodulation device that is implanted beneath the skin to provide continuous stimulation to specific nerves associated with chronic migraine. This technology aims to reduce the frequency and severity of migraine attacks for individuals who do not find relief through traditional medications.

Shoulder Innovations develops InSet™ Glenoid fixation technology, which utilizes a proprietary curved fin geometry and interlock porous coating to enhance rotational stability and promote bony ingrowth. This technology addresses the issue of inadequate fixation in traditional shoulder arthroplasty, improving procedure longevity and patient outcomes.

Tarsus Pharmaceuticals develops targeted therapies for diseases with high unmet medical needs, including the first FDA-approved treatment for Demodex blepharitis, XDEMVY® (lotilaner ophthalmic solution) 0.25%. The company is advancing a robust pipeline of investigational treatments for conditions such as papulopustular rosacea and Lyme disease, addressing significant gaps in available therapies.

uLab Systems provides a digital dental treatment planning software that enables orthodontists to design customized aligner treatment plans in as few as 10 minutes using AI-driven segmentation. This technology allows practitioners to efficiently manage hybrid and combo treatments while reducing lab costs and increasing profitability on complex cases.

XII Medical develops minimally invasive neuromodulation therapies for obstructive sleep apnea, enhancing patient access to effective treatment options. Their technology aims to improve clinical outcomes by simplifying the therapeutic process and reducing the need for invasive procedures.